Novo Nordisk is predicted to have significant future growth potential, provided it resolves challenges in manufacturing capacity, insurance coverage, and drug costs, and if no major unforeseen negative side effects emerge.
"this is something that we still think there is so much huge potential with this particular investment and we think about this because of a couple reasons so the first is manufacturing capacity there is so much demand for these particular drugs produced by this company that Novo nordis cannot keep up with the demand... We are continuing to invest in it we think that once it fixes its issues with manufacturing capacity insurance and cost and also as we're monitoring the side effects and the impact of the news that it could have on this company we think that there's a lot of potential"
